Fig. 6.

Anti-tumor activity of 4H11 CAR T cells secreting ESK1-BiTE in vivo. A Muc16 low SKOV3 cells (2 million cells) were injected ip into NSG mice and tumor engraftment was confirmed on day 5 by bioluminescent imaging. 4H11 CAR T cells, ESK1 BiTE-secreting 4H11 CAR T cells, or control mock-T cells (2 million/mouse) were injected ip, followed by injection ip of two million activated T cells (mock-T from the same donor) on the next day (BioRender). B Tumor burden was monitored by bioluminescent imaging on day 12, 19, and 26. C Tumor burden of mice in panel A was calculated by summing the luminescent signal of each mouse, and average signal for each group (n = 4 per group, except for tumor alone group n = 3), plus minus SD, is plotted. P value was determined by unpaired t student test (D). Survival of mice from panel A experimental groups was monitored, and the significance was evaluated by Mantel–Cox P test. * =  < 0.05; ** =  < 0.01